YSYukitaka Shizukuda

Yukitaka Shizukuda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yukitaka Shizukuda has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exercise Capacity of Cardiac Asymptomatic Hereditary Hemochromatosis Subjects

    by Yukitaka Shizukuda, Charles D. Bolan, Dorothy J. Tripodi, Yu-Ying Yau, Kevin P. Smith, Ross Arena, Myron A. Waclawiw, Susan F. Leitman, Douglas R. Rosing

    21 normal control subjects who were New York Heart Association functional class I underwent metabolic stress testing using the Bruce protocol at the clinical center of the National Institutes of Health. Exercise capacity was assessed with minute ventilation (V˙E), oxygen uptake (V˙O2), and carbon dioxide production (V˙CO2) using a breath-by-breath respiratory gas analyzer. Results: The exercise capacity of HH subjects was not statistically different from that of control subjects (exercise time 564 ± 135 vs 673 ± 175 s, P = 0.191; peak V˙O2 29.6 ± 6.4 vs 32.5 ± 6.7 mL·kg−1·min−1, P = 0.109; ventilatory threshold 19.0 ± 3.4 vs 21.0 ± 5.0 mL·min−1·kg−1, P = 0.099; data are for HH vs control subjects). Ventilatory efficiency was comparable between groups (V˙E/V˙CO2 slope 23.7 ± 3.2 vs 23.4 ± 4.2, P = 0.791). No significant correlation between the markers of iron levels and the markers of exercise capacity was noted. Iron depletion by 6-month phlebotomy therapy in 18 subjects who were newly diagnosed did not affect exercise testing variables (exercise time 562 ± 119 vs 579 ± 118 s, P = 0.691; peak V˙O2 29.5 ± 3.7 vs 29.1 ± 4.7 mL·kg−1·min−1, P = 0.600; ventilatory threshold 18.5 ± 2.8 vs 17.9 ± 3.8 mL·kg−1·min−1, P = 0.651; data are from before and after phlebotomy therapy). Abnormal ischemic electrocardiographic responses and complex arrhythmias were more frequently seen in HH subjects. Conclusions: The aerobic exercise capacity of asymptomatic HH subjects seems not to be statistically different from that of normal subjects. The iron levels do not seem to affect exercise capacity in asymptomatic HH subjects....


  • Significance of Left Atrial Contractile Function in Asymptomatic Subjects With Hereditary Hemochromatosis

    by Yukitaka Shizukuda, Charles D. Bolan, Dorothy J. Tripodi, Yu-Ying Yau, Tammy T. Nguyen, Gilberto Botello, Vandana Sachdev, Stanislav Sidenko, Inez Ernst, Myron A. Waclawiw, et al.


  • Left Ventricular Systolic Function During Stress Echocardiography Exercise in Subjects With Asymptomatic Hereditary Hemochromatosis

    by Yukitaka Shizukuda, Charles D. Bolan, Dorothy J. Tripodi, Yu-Ying Yau, Kevin P. Smith, Vandana Sachdev, Charles W. Birdsall, Stanislav Sidenko, Myron A. Waclawiw, Susan F. Leitman, et al.


  • Is Functional Capacity Related to Left Atrial Contractile Function in Nonobstructive Hypertrophic Cardiomyopathy?

    by Yukitaka Shizukuda, Vandana Sachdev, Lameh Fananapazir, Dorothy Tripodi, Saidi A. Mohiddin, Andrew E. Arai, Myron A. Waclawiw, Jonathan F. Plehn

    The mechanisms underlying reduced exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy (NHCM) could include perturbations of ventricular relaxation, diastolic compliance, or compensatory atrial systolic function. We hypothesized that a loss of atrial contractility in NHCM patients leads to reduced functional capacity. To test this hypothesis, we compared resting noninvasive left atrial ejection phase indices in 49 consecutive patients with NHCM (ages 36+/-10 years; 41% female) and normal left ventricular ejection fraction (mean, 68%+/-8%) with objective metabolic exercise parameters. Left atrial active emptying fraction, ejection force, and kinetic energy failed to predict exercise capacity. Only left atrial total and active emptying volumes correlated weakly with minute volume/CO2 production slope (r=0.31 and r=0.33; p<0.05 for both). Furthermore, when subjects were stratified by New York Heart Association symptomatology, exercise parameters--but not atrial contractility--differed between groups. These data, obtained at rest, fail to suggest that NHCM-related heart failure symptoms are due to an atrial myopathy.


  • Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice

    by Yukitaka Shizukuda, Satoaki Matoba, Omar Y. Mian, Tammy Nguyen, Paul M. Hwang

    Use of the chemotherapeutic agent doxorubicin (Dox) is limited by dose-dependent cardiotoxic effects. The molecular mechanism underlying these toxicities are incompletely understood, but previous results have demonstrated that Dox induces p53 expression. Because p53 is an important regulator of the cell birth and death we hypothesized that targeted disruption of the p53 gene would attenuate Dox-induced cardiotoxicity. To test this, female 6–8 wk old C57BL wild-type (WT) or p53 knockout (p53 KO) mice were randomized to either saline or Dox 20 mg/kg via intraperitoneal injection. Animals were serially imaged with high-frequency (14 MHz) two-dimensional echocardiography. Measurements of left ventricle (LV) systolic function as assessed by fractional shortening (FS) demonstrated a decline in WT mice as early as 4 days after Dox injection and by 2 wk demonstrated a reduction of 31± 16% (P < 0.05) from the baseline. In contrast, in p53 KO mice, LV FS was unchanged over the 2 wk period following Dox injection. Apoptosis of cardiac myocytes as measured by the TUNEL and ligase reactions were significantly increased at 24 h after Dox treatment in WT mice but not in p53 KO mice. After Dox injection, levels of myocardial glutathione and Cu/Zn superoxide dismutase were preserved in p53 KO mice, but not in WT animals. These observations suggest that p53 mediated signals are likely to play a significant role in Dox-induced cardiac toxicity and that they may modulate Dox-induced oxidative stress.


  • Effect of a Histone Deacetylase Inhibitor on Human Cardiac Mass

    by Yukitaka Shizukuda, Richard L. Piekarz, Susan E. Bates, Vandana Sachdev, Toren Finkel, Douglas R. Rosing